At A Glance
M3 MI's MARS Consumer Health Study empowers healthcare advertisers to create personalized campaigns by offering nuanced audience insights. By layering behavioral and engagement attributes, MARS enables accurate targeting, driving stronger engagement, improved ad recall, and measurable campaign outcomes across connected TV (CTV), social, and display channels.In our Ask the Expert Series, we interview leaders from our partner organizations who are helping lead their brands to new heights in AdTech. Today’s interview is with Dan Lynch a Senior Manager, Insights and Analysis at M3 MI, the company behind the MARS Consumer Health Study and MARS Audiences.
Audience impact across health vertical
Which healthcare advertisers see the greatest impact from MARS audiences? Could you share an example of how health marketers have successfully utilized your data to achieve specific campaign goals, such as patient engagement, awareness, or adherence?
We’re seeing a clear shift in healthcare advertising away from generic, one-size-fits-all campaigns. With MARS, advertisers from pharmaceuticals, over-the-counter (OTC), health insurance companies, and hospitals are seeing the greatest impact by defining highly specific patient and caregiver personas and using those insights to build personalized media plans and deliver unique messaging by segment. As a result, our partners are seeing stronger engagement, increased ad recall, and more effective outcomes because they’re speaking directly to what matters most to each audience.
Media agencies who utilize the MARS Consumer Health Study to build their strategic marketing plans are seeing a great impact by then taking those strategic targets and activating them. Those who are not activating those audiences are really missing out on bringing their strategy to consumer screens.
Building stronger health campaigns with advanced segmentation
What key health-related audience segments does MARS offer?
While other competitors may offer caregiver segments by condition, we go further by layering engagement levels, such as caregivers actively involved in medical decisions or those who regularly discuss care with physicians. Similarly, for patients, we don’t stop at identifying over 60 health conditions; we add behavioral dimensions like whether they’re proactive in managing their health or primarily doctor-led. These nuanced attributes allow advertisers to craft personalized campaigns that resonate on a much deeper level. We can also look at patients that are willing to pay more for an Rx not covered by their insurance, which has been a trend with GLP-1s.
How can health advertisers use these segments to craft more personalized and effective campaigns?
Advertisers can use MARS’ advanced segmentation to move beyond simple demographics or condition-based targeting by layering behavioral and engagement attributes for greater relevance and impact. With MARS, a single condition can be the starting point for building multiple test-and-learn audiences to identify prime prospects. For example, GLP-1 patients have diverse treatment journeys; some pay out-of-pocket due to lack of insurance coverage, others switch brands for cost savings, and some purchase directly through patient websites. Each of these scenarios represents a distinct audience that can be created using MARS data, enabling highly personalized activation strategies.
Data sourcing and quality
How does MARS source and curate consumer data relevant to health audiences?
Our audiences are survey-based, first-party data built from the MARS Consumer Health Study and Kantar’s trusted LifePoints Panel. We do not use medical claims, insurance data, or personal health records; our data is 100% self-reported. The study has over 5,000 different healthcare data points used to create syndicated and custom audiences. Our syndicated audiences are curated based on marketplace trends (e.g., we’ve added more information on GLP-1s), client feedback for enhancements to the MARS study, and reaching audiences medical claims data cannot (e.g., caregivers, treatment satisfaction, act based on healthcare advertising).
What data quality standards do you follow, and how do you ensure consistency and reliability, especially for sensitive or regulated health-related data?
M3 MI is part of M3 Global Research which is committed to transparency and high-quality data with ISO (International Organization for Standardization) certifications. These certifications demonstrate that our research practices align with international regulations.
In a crowded data marketplace, what unique attributes set MARS apart, particularly for health advertisers?
We don’t just identify patients or caregivers, we uncover their motivations, preferences, and behaviors, enabling advertisers to build highly targeted and meaningful audiences that competitors simply can’t replicate.
The MARS Consumer Health Study offers an extensive range of data for audience building, spanning healthy living profiles, OTC, vitamins, and prescription purchasing behaviors, as well as media consumption habits and lifestyle activities.
How MARS ensures regulatory compliance
What measures does MARS take to maintain data privacy and regulatory compliance?
We take a privacy-first approach to exceed all Network Advertising Initiative (NAI), Health Insurance Portability and Accountability Act (HIPAA), and California Consumer Privacy Act (CCPA) regulations. Since the data to build our audiences is self-reported via the MARS Consumer Health Study, we do not use PII data. We also take the following steps to maintain data privacy and compliance:
- State regulatory compliance: We proactively exclude survey respondents for audience seeds from certain states with consumer privacy laws that preclude audience data use
- Consent and transparency: Survey panelists are required to double-opt-in to all data usage terms before participating in the MARS study. Our panel partner’s privacy policy clearly explains use cases such as look-alike modeling and audience creation.
- Privacy-safe modeling: Data is scaled using propensity models built from an offline, people-based national consumer database. All seed survey data is removed from final models to eliminate any risk of re-identification, ensuring respondents are never targeted directly based on their survey responses.
Click here for full details on M3 MI’s privacy policy
How do these efforts help advertisers navigate an evolving regulatory landscape while ensuring ethical standards?
By relying solely on double opt-in, self-reported data, and removing identifiers, we guarantee that our approach is 100% privacy-safe and compliant. This gives advertisers confidence that our audiences are built on ethical, transparent practices without compromising consumer trust.
Success stories
Could you share a recent success story where a health advertiser achieved significant campaign improvements using M3 MI’s MARS data? What were the key factors behind that success, such as ROI, engagement lift, or conversion rates?
One recent success story involved a diabetes medical device advertiser trying to breakthrough in a cluttered marketing landscape. Their initial broad, non-personalized media campaign delivered lower than expected digital engagement. To address this, the company conducted segmentation research and identified three distinct patient personas. However, the research lacked actionable media insights and a way to effectively reach these personas in the digital world.
That’s where MARS data came in. Using the MARS Consumer Health Study, M3 MI mapped the existing personas to uncover each group’s unique media habits. These insights enabled the media agency to design tailored strategies for each persona. Additionally, M3 MI built custom, propensity-modeled persona audiences for activation across CTV, social, and display channels, ensuring precise targeting and personalized messaging. This strategic shift to personalized persona marketing transformed the campaign from a one-size-fits-all approach to a patient-first model. The company saw a significant lift in website engagement and a measurable increase in ROI.
Resources to maximize your campaigns
Where can readers find additional resources, case studies, or insights to learn more about MARS audience solutions?
Interested healthcare marketers can explore additional resources by visiting our Audience Solutions page. There, they’ll find a comprehensive overview, a detailed taxonomy of syndicated audiences, and other helpful materials. For personalized support or further information on customized audiences, they can also reach us directly at info@M3-MI.com.
Contact us
About our expert
Dan Lynch
Senior Manager, Insights and Analysis, M3 MI
Dan Lynch is a seasoned leader in strategic marketing insights and activation with over 20 years at healthcare focused media agencies. At M3 MI, he helps pharmaceutical companies, media partners, and agencies leverage our syndicated research to address critical business needs. Dan is also a lead of the MARS addressable audience initiative, applying his expertise in developing unique audience personas from our data and activating them across programmatic channels.
About M3 MI
M3 MI, a division of M3 USA, is the leading provider of unbiased syndicated research for the healthcare industry. We specialize in media measurement, advertising intelligence, and audience insights and activation. Leveraging robust datasets, rigorous methodologies, and decades of healthcare expertise, M3 MI delivers a deeper understanding of patients, caregivers, and healthcare professionals, their behaviors, attitudes, media habits, and communication preferences. These insights empower marketers to make informed, data-driven decisions.
Latest posts
The Tapad Device GraphTM Had Twice the Precision and Three Times the Scale as Next Competitor New York, September 14, 2016 – Just-released findings of a Hotels.com® study revealed that Tapad’s (part of Experian) cross-screen marketing technology achieved the highest levels of precision and scale among competitors. According to the leading online accommodation booking website, after a rigorous, three-and-a-half month vendor analysis, Tapad achieved twice the precision of the next highest-scoring cross-screen offering and three times greater scale. The two other companies evaluated were not named. Said Helene Cameron-Heslop, Senior Manager of Analytics of the Hotels.com brand, “Our team implemented an extremely rigorous vetting of open, cross-screen technology vendors. At the outset, we assumed we would have to compromise on either scale or accuracy – particularly given the importance to our brand of operating in a privacy-safe setting. We were surprised to find a complete package, but Tapad’s Device Graph won out on scale, accuracy and privacy; making our choice of partners very clear.” In another metric critical to the Hotels.com brand, The Tapad Device GraphTM was eight times more “unique” than the next closest offering, meaning Tapad’s graph was found to have a much greater number of connections not seen in any of the other graphs. In addition to precision, uniqueness and scale, the Tapad Device GraphTM was found to have: ● 100% higher recall● 47% more incremental matches● 53% higher North American market coverage● 101% higher F-Score* “A valuable cross-device solution should enable partners to get everything they’re looking for from a single vendor,” said Tapad Founder and CEO, Are Traasdahl. “We are deeply impressed with how thorough Hotels.com was in their vetting, and we confidently tackle the complex challenges of the martech industry thanks to our superior technology. Everyone loves a bake-off, and Tapad is no exception – delivering best-in-class results in areas that really count.” *F-score is a statistical measurement that takes precision and recall together. The calculation is 2*(precision*recall)/precision + recall). It gives you one number instead of two numbers to look at and judge performance. Contact us today
Five Norwegian startups selected to establish U.S. presence NEW YORK, Aug. 15, 2016 /PRNewswire/ — Tapad, the leader in cross-device marketing technology and now a part of Experian, has announced its new entrepreneurial mentorship initiative, the Propeller Program. Five early-stage startups from Norway have been chosen by Are Traasdahl, native of Norway and Tapad’s CEO and founder. The selected companies will share Tapad’s New York City workspace, receive C-level guidance and help establish a U.S. presence. The following companies have been selected to participate in the inaugural Propeller Program – a 12-month program beginning September 19, 2016: Bubbly – Developers of a platform that enables in-store customer feedback with dashboards and tools that facilitate real-time store response BylineMe – A marketplace for freelancers, publishers and brands to connect for content creation and distribution services Eventum – A property-sharing group that digitally assists in securing venues for meetings and corporate events Xeneta – A database that organizes the best contracted freight rates in real time and on demand “We are supporting startups that we feel represent the future of service offerings,” said Traasdahl. “It is with incredible pride that we invite these entrepreneurial teams from Norway to join us in New York Citythis year. Mentorship opportunities for early-stage companies are so important, particularly for those based outside the U.S. I look forward to giving the Propeller Program participants access to the expertise of my seasoned team and to our wide network of resources. Hopefully, it will be a game-changing year for many of them.” Contact us today
As partnership deals mount, aggressive hiring underway for unified cross-screen technology leaders NEW YORK, July 19, 2016 /PRNewswire/ – Tapad, the leader in cross-device marketing technology and now a part of Experian, has announced plans for aggressive expansion in the Asia Pacific (APAC) region. This move capitalizes on Tapad's exceptional performance for brands and marketing technology companies in North America and Europe. With it's proprietary Tapad Device Graph™, the company will enable global, regional and local clients and partners to understand, monetize and measure marketing to users across screens. The Tapad Device Graph is recognized as the most accurate, scalable cross-screen solution in the market today. The decision to expand into APAC was based on increased demand from global, as well as local, brands and clients, many of which have a strong market presence throughout the region. In addition to expanding its roster of world-class data partners, plans include building a world-class team in Singapore. Over the next few months, Tapad APAC will also establish local entities in additional markets. To accelerate its ramp-up, Tapad APAC is actively recruiting in many areas, ranging from skilled and experienced solutions engineers to seasoned sales and marketing professionals. "Tapad is thrilled to be answering the call for cross-device excellence in APAC," said Pierre Martensson, GM of Tapad APAC. "Our Device Graph is adding millions of devices daily and achieves unmatched levels of scale and accuracy while protecting consumer privacy. This meets a critical need in the region." Tapad appointed Martensson as General Manager of Tapad APAC in May, kicking off expansion in the region. Martensson comes to Tapad with nearly a decade of operations experience throughout APAC, having transformed, developed and grown global organizations. To learn more about partnership and employment opportunities available with Tapad in APAC, visit www.experian.com/careers. Contact us today